GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Marvel Biosciences MRVL.V · CAD

N/A · TSX Venture · 🇨🇦 Canada

Compare

0.12

0.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CAD, from our data supplier.

FY2025

Net income

−C$2.2m

FY2020FY2025

Free cash flow

−C$1.2m

FY2020FY2025

Shareholders' equity

−C$4.0m

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Gross profit−C$547,366−C$302,023−C$887,516−C$1.4m−C$613,099−C$265,200
Research and developmentC$547,366C$302,023C$887,516C$1.4m——
Operating income−C$1.2m−C$1.3m−C$2.2m−C$2.5m−C$1.1m−C$954,771
Net income−C$2.2m−C$1.7m−C$2.3m−C$2.6m−C$3.0m−C$955,657
Diluted earnings per share-0.04-0.04-0.06-0.07-0.09-0.03

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assetsC$326,715C$491,311C$672,389C$913,541C$2.5mC$295,987
Total liabilitiesC$4.3mC$3.3mC$2.4mC$718,005C$112,477C$177,183
Debt—C$1.7mC$1.0m———
Shareholders' equity−C$4.0m−C$2.8m−C$1.7mC$195,536C$2.4mC$118,804
Shares outstanding53m45m40m37m33m33m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−C$1.2m−C$1.2m−C$1.3m−C$2.2m−C$1.4m−C$538,535
Free cash flow−C$1.2m−C$1.2m−C$1.3m−C$2.2m−C$1.4m−C$538,535

Latest quarters

By quarter end

Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024
Gross profit−C$72,144−C$5,258−C$57,457−C$250,559−C$382−C$285,002−C$11,423—
Operating incomeC$118,197−C$270,889−C$263,357−C$347,987−C$275,321−C$393,395−C$231,980—
Net incomeC$436,706−C$295,578−C$342,263−C$1.2m−C$257,411−C$485,606−C$278,245−C$591,653
Diluted earnings per share0.01-0.01-0.01-0.02-0.00-0.01-0.01-0.01
Total assetsC$471,733C$319,615C$683,056C$326,715C$500,512C$219,075C$228,645C$491,311
DebtC$624,000———C$710,000C$1.7mC$1.7mC$1.7m
Shareholders' equity−C$2.7m−C$3.9m−C$3.7m−C$4.0m−C$2.9m−C$3.5m−C$3.1m−C$2.8m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-21.2%5.5%—
Net income-4.7%18.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-3.2-4.6-1.4-1.8-1.5

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.